...
首页> 外文期刊>Journal of Clinical Microbiology >Rapid Detection of Fluoroquinolone-Resistant and Heteroresistant Mycobacterium tuberculosis by Use of Sloppy Molecular Beacons and Dual Melting-Temperature Codes in a Real-Time PCR Assay
【24h】

Rapid Detection of Fluoroquinolone-Resistant and Heteroresistant Mycobacterium tuberculosis by Use of Sloppy Molecular Beacons and Dual Melting-Temperature Codes in a Real-Time PCR Assay

机译:通过实时PCR分析中使用草率分子信标和双重解链温度码快速检测耐氟喹诺酮和耐异性结核分枝杆菌

获取原文
           

摘要

Fluoroquinolones (FQ) are important second-line drugs to treat tuberculosis; however, FQ resistance is an emerging problem. Resistance has been mainly attributed to mutations in a 21-bp region of the Mycobacterium tuberculosis gyrA gene, often called the quinolone resistance-determining region (QRDR). We have developed a simple, rapid, and specific assay to detect FQ resistance-determining QRDR mutations. The assay amplifies the M. tuberculosis gyrA QRDR in an asymmetrical PCR followed by probing with two sloppy molecular beacons (SMBs) spanning the entire QRDR. Mutations are detected by melting temperature (Tm) shifts that occur when the SMBs bind to mismatched sequences. By testing DNA targets corresponding to all known QRDR mutations, we found that one or both of the SMBs produced a Tm shift of at least 3.6°C for each mutation, making mutation detection very robust. The assay was also able to identify mixtures of wild-type and mutant DNA, with QRDR mutants identified in samples containing as little as 5 to 10% mutant DNA. The assay was blindly validated for its ability to identify the QRDR mutations on DNA extracted from clinical M. tuberculosis strains. Fifty QRDR wild-type samples, 34 QRDR mutant samples, and 8 heteroresistant samples containing mixtures of wild-type and mutant DNA were analyzed. The results showed 100% concordance to conventional DNA sequencing, including a complete identification of all of the mixtures. This SMB Tm shift assay will be a valuable molecular tool to rapidly detect FQ resistance and to detect the emergence of FQ heteroresistance in clinical samples from tuberculosis patients.
机译:氟喹诺酮类药物(FQ)是治疗肺结核的重要二线药物。但是,FQ抵抗是一个新出现的问题。耐药性主要归因于结核分枝杆菌gyrA 基因21 bp区域的突变,通常称为喹诺酮耐药性确定区域(QRDR)。我们已经开发出一种简单,快速且特异性的检测方法来检测FQ耐药性决定的QRDR突变。该测定法扩增了 M。在非对称PCR中检测结核性gyrA QRDR,然后用横跨整个QRDR的两个马虎分子信标(SMB)进行探测。当SMB与不匹配的序列结合时,通过解链温度( T m )的变化检测突变。通过测试与所有已知QRDR突变相对应的DNA靶标,我们发现一个或两个SMB产生的每个突变的 T m 位移至少为3.6°C,突变检测非常可靠。该测定法还能够鉴定野生型和突变型DNA的混合物,而在含有低至5%至10%突变型DNA的样品中鉴定出QRDR突变型。该测定法能够盲目的验证其鉴定从临床结核分枝杆菌菌株提取的DNA上的QRDR突变的能力。分析了50个QRDR野生型样品,34个QRDR突变样品和8个包含野生型和突变DNA混合物的异抗性样品。结果显示与常规DNA测序100%一致,包括对所有混合物的完整鉴定。这种SMB T m 迁移分析将是一种有价值的分子工具,可快速检测结核病患者临床样品中的FQ耐药性并检测FQ异抗性的出现。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号